I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
1. I-Mab acquires Bridge Health for upstream rights to CLDN18.2 antibody. 2. Acquisition unencumbers givastomig from future royalties and reduces milestones. 3. Givastomig shows an 83% objective response rate in recent trials. 4. I-Mab plans topline results for givastomig by Q1 2026. 5. Givastomig targets gastric cancer with additional potential in other tumors.